Drug company Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) completed the placing of 5,918,000 shares to at least six investors at HK$331.8 apiece to raise net proceeds of a little over HK$1.94 billion, a Thursday Hong Kong bourse filing said.
Proceeds will be used for the R&D, trials, registration, manufacturing, and commercialization of products; external collaborations; product pipeline portfolio expansion; and replenishment of working capital among other uses.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。